Opinion|Videos|August 21, 2024
CML Treatment: Scenarios that Necessitate Switching Therapy
Jorge E. Cortes, MD, details clinical scenarios that indicate a need to switch therapies for patients with chronic myeloid leukemia.
Advertisement
Episodes in this series
This program was made possible with support from Novartis Pharmaceuticals.
Video content above is prompted by the following:
- In which scenarios do you consider switching CML therapies, and how do you approach that conversation with patients? How does the patient experience change when switching therapies?
Advertisement
Related to this article
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
Advertisement
Advertisement
Trending on CURE
1
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
2
3 More Lung Cancer Breakthroughs From WCLC 2026
3
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
4
FDA Approves Inluriyo Plus Verzenio for Certain Advanced Breast Cancers
5